News | February 16, 2022
Mankind Pharma acquires two brands from Dr Reddy’s
The entire integration and transition of the brands is expected to be completed by March 2022
The entire integration and transition of the brands is expected to be completed by March 2022
Lupin has reported consolidated financial results for the period ended December 31, 2021
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The company reports revenue growth of 26% and PAT growth of 21% YoY
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
Subscribe To Our Newsletter & Stay Updated
